IP Library Granted Patent US 6,881,405
Granted Patent B2
US 6,881,405 · App. 09/332,866 · Granted Apr 19, 2005

Reagents and methods for inducing an immune response to prostate specific antigen

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,881,405
App. No.
09/332,866
Granted
Apr 19, 2005
Kind
B2
Abstract

The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.

Claims (9)

1. A method for inducing an immune response comprising administering to a mammal an antibody or antigen-binding fragment thereof that specifically binds to an epitope of circulating prostate specific antigen, said epitope being the epitope to which a monoclonal antibody produced by a hybridoma that has ATCC Designation Number 1-18-12526 specifically binds.

2. The method of claim 1 , wherein the antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is conjugated to an immunogenic carrier.

4. The method of claim 3 , wherein the immunogenic carrier is keyhole limpet hemocyanin.

5. The method of claim 1 , wherein the antibody is selected from a monoclonal antibody, a single chain antibody, and a humanized antibody.

6. The method according to claim 1 , wherein the antibody or antigen binding fragment thereof is a xenogenic antibody or antigen-binding fragment thereof.

7. The method according to claim 1 , wherein the antibody or antigen-binding fragment thereof is formulated with an adjuvant.

8. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is formulated at a dose of from about 0.1 μg to about 2 mg per kilogram of body weight of the mammal.

9. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is formulated at a dose of from about 1.0 μg to about 200 μg per kilogram of body weight of the mammal.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2015
From: QUEST PHARMATECH INC.
To: ONCOQUEST INC.
Reel/Frame 036971/0776 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2013
From: ALTAREX MEDICAL CORP.
To: QUEST PHARMATECH INC.
Reel/Frame 030573/0225 →
DISCHARGE OF SECURITY INTEREST Recorded Nov 28, 2005
From: UNITED THERAPEUTICS CORPORATION
To: ALTAREX MEDICAL CORP.
Reel/Frame 017262/0502 →
SECURITY AGREEMENT Recorded Mar 1, 2004
From: ALTAREX MEDICAL CORP.
To: UNITED THERAPEUTICS CORPORATION
Reel/Frame 014384/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2004
From: ALTAREX CORP.
To: ALTAREX MEDICAL CORP.
Reel/Frame 014384/0305 →